Tag - Celltrion’s Rituxan biosimilar

Celltrion’s Rituxan biosimilar wins European approval

South Korea’s Celltrion announced Wednesday that the European Medicines Agency has granted sales approval to Truxima, its biosimilar drug referencing Roche’s blockbuster lymphatic cancer drug Rituxan. Truxima is the first ever Rituxan (rituximab) biosimilar to be approved by the European drug regulator, as well as the first ever Europe-approved biosimilar monoclonal antibody used to target cancer. Biosimilars are cheaper, near replicas of living cell-based biologic drugs whose patents have expired. The recent emergence of these alternative drugs have begun to threaten [...]